17.74
-0.26 (-1.44%)
| Penutupan Terdahulu | 18.00 |
| Buka | 17.78 |
| Jumlah Dagangan | 189,912 |
| Purata Dagangan (3B) | 1,251,146 |
| Modal Pasaran | 2,093,375,360 |
| Harga / Jualan (P/S) | 612.75 |
| Harga / Buku (P/B) | 5.24 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2026 |
| Margin Operasi (TTM) | -1,525.50% |
| EPS Cair (TTM) | -3.01 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 184.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.55% |
| Nisbah Semasa (MRQ) | 10.49 |
| Aliran Tunai Operasi (OCF TTM) | -152.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -117.16 M |
| Pulangan Atas Aset (ROA TTM) | -33.54% |
| Pulangan Atas Ekuiti (ROE TTM) | -69.21% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Immunome, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | 1.17 |
|
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 11.48% |
| % Dimiliki oleh Institusi | 83.28% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Redmile Group, Llc | 30 Jun 2026 | 4,911,590 |
| Primecap Management Co/Ca/ | 30 Jun 2026 | 4,581,431 |
| Enavate Sciences Gp, Llc | 30 Jun 2026 | 3,613,799 |
| Silverarc Capital Management, Llc | 30 Jun 2026 | 2,017,009 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |